多omics映射识别了CYBA介导的线粒体功能障碍,通过Nrf2途径在动脉样硬化中驱动巨细胞极化和铁亡
APL bioengineering
|February 2, 2026
概括
CYBA调节巨细胞中的线粒体功能,影响动脉样硬化进展. 抑制CYBA可降低炎症和氧化应激,为心血管疾病提供潜在的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 线粒体医学 线粒体医学
背景情况:
- 动脉样硬化 (AS) 涉及巨驱动的炎症和线粒体功能障碍.
- 在AS中,CYBA在将线粒体健康与巨细胞行为联系起来的作用尚不清楚.
- CYBA基因变异与心血管风险有关.
研究的目的:
- 在AS期间调查CYBA在线粒体-巨细胞交叉交流中的功能.
- 确定CYBA在氧化应激,巨细胞两极分化和铁亡中的作用.
- 探索CYBA作为AS的治疗目标.
主要方法:
- 综合的AS免疫微环境的多omics分析.
- 机器学习和单细胞RNA测序以识别关键基因.
- 使用ApoE-/-小鼠和腺相关病毒介导的CYBA敲击的体内研究.
- 用氧化低密度脂蛋白 (ox-LDL) 刺激的巨体进行了体外实验.
- 涉及Nrf2通路激活的机制研究.
主要成果:
- 在AS中,CYBA被确定为氧化应激的关键调节者.
- 在动脉样硬化病变内的巨细胞中,CYBA表达被上调.
- 在体内减弱AS斑块形成和线粒体损伤.
- 在体外,CYBA抑制减少了ox-LDL诱导的线粒体功能障碍,炎症和铁亡.
- CYBA缺乏促进了Nrf2通路的激活.
结论:
- CYBA充当线粒体检查点,抑制Nrf2介导的抗氧化反应.
- 这种抑制促进了巨细胞炎症两极分化和AS中的铁亡.
- 准CYBA是一个有前途的治疗策略,可以缓解AS的进展.
相关概念视频
Molecular Shape and Polarity
75.7K
Dipole Moment of a Molecule
75.7K
Group Polarization
39.2K
Group polarization is the strengthening of an original group attitude following the discussion of views within a group (Teger & Pruitt, 1967). That is, if a group initially favors a viewpoint, after discussion the group consensus is likely a stronger endorsement of the viewpoint. Conversely, if the group was initially opposed to a viewpoint, group discussion would likely lead to stronger opposition.
39.2K
Animal Mitochondrial Genetics
9.2K
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
9.2K
Atherosclerosis III: Management
412
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
412
Atherosclerosis I: Introduction
1.1K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.1K
Energy to Drive Translocation
2.8K
Mitochondrial protein import is powered by two distinct energy sources: ATP hydrolysis and electrochemical potential across the inner membrane. Newly synthesized precursors are bound by cytosolic chaperones of the Hsp70 family, which guide them to the import receptors on the mitochondrial surface. Utilizing the energy of ATP hydrolysis, Hsp70 chaperones transfer these precursors to the TOM receptors on the mitochondrial outer membrane.
Generally, polypeptides are unfolded by two distinct...
Generally, polypeptides are unfolded by two distinct...
2.8K


